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Pancreatic neuroendocrine tumors (pNETs) are infrequent malignancies which manifest in both
functional (hormone-secreting) and more commonly non-functional (non-secreting) forms. The oral
multitargeted tyrosine kinase inhibitor sunitinib and mammalian target of rapamycin (mTOR) inhibitor
everolimus are approved as targeted therapies for patients with well-differentiated, non-resectable dis-
ease and evidence of disease progression. The recent approval of sunitinib for the management of
advanced pNET is based on a continuous daily dosing (CDD) schedule that differs from the intermittent
4 weeks on/2 weeks off (4/2) schedule approved for sunitinib in advanced renal cell carcinoma (RCC) and
imatinib-resistant gastrointestinal stromal tumor (GIST). Therefore, although clinicians may be familiar
with therapy management approaches for sunitinib in advanced RCC and GIST, there is less available
experience for the management of patients with a CDD schedule. Here, we discuss the similarities and
differences in the treatment of pNET with sunitinib compared with advanced RCC and GIST. In particular,
we focus on the occurrence and management of sunitinib-related toxicity in patients with pNET by
drawing on experience in these other malignancies. We aim to provide a relevant and useful guide for
clinicians treating patients with pNET covering the management of events such as fatigue, mucositis,
hand–foot syndrome, and hypertension.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Pancreatic neuroendocrine tumors (pNETs) are generally
regarded as infrequent malignancies. However, the reported inci-
dence of pNETs is increasing, with Surveillance, Epidemiology
and End Results (SEER) records showing a clear upward trend for
the period 1973–2003 [1]. In the US alone, a conservative estimate
of prevalence in 2004 was 32,353 individuals [1]. pNETs are
associated with favorable survival relative to other tumor types.
For individuals with well-differentiated (grades 1 and 2) regional
disease, the median survival is 9.25 years, with 5-year survival
rates of 62%; for those with metastatic disease, these values fall
to 2.25 years and 27%, respectively [1].
pNETs are divided into two groups (functional and non-
functional) according to whether or not the tumor secretes a
biologically active substance. pNETs are predominantly non-func-
tional and thus are not associated with hormone hypersecretionsyndromes. Diagnosis of such tumors is often serendipitous at
early stages; advanced-stage diagnosis usually stems from symp-
toms arising from tumor bulk. Of patients with advanced disease,
60–85% have liver metastases at diagnosis [2,3]. Where surgical
resection is possible, it is the treatment option of choice for both
locoregional and metastatic disease according to the National
Comprehensive Cancer Network (NCCN) treatment guidelines [3].
Where disease is non-resectable and patients are symptomatic,
or have clinically signiﬁcant tumor burden or progressive disease,
treatment options include hepatic regional therapy, cytoreductive
surgery, cytotoxic chemotherapy, and somatostatin analogues to
control symptoms arising from hormone hypersecretion (NCCN
treatment guidelines) [3]. The development of targeted agents for
pNET has primarily focused on the vascular endothelial growth fac-
tor receptor (VEGFR) and mammalian target of rapamycin (mTOR).
Sunitinib and everolimus, targeting the VEGF/VEGFR and mTOR
pathways, respectively, have recently been approved for the treat-
ment of non-resectable pNET. Although conventional tumor
response rates (per Response Evaluation Criteria in Solid Tumors;
RECIST) are low, these agents are associated with signiﬁcant
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agents have been added to the standard armamentarium for the
treatment of non-resectable pNET in the clinical setting. At the
time of its approval in the European Union in December 2010,
sunitinib represented the ﬁrst new treatment option approved
for pNET for 20 years; approval by the US Food and Drug Adminis-
tration followed in May 2011 [4,5].
Sunitinib malate is an oral multitargeted tyrosine kinase inhib-
itor of VEGFRs, platelet-derived growth factor receptors (PDGFRs),
KIT, FLT3, CSF-1R, and RET [6] approved in the US and EU for the
treatment of progressive, well-differentiated pNET in patients with
unresectable locally advanced or metastatic disease. Phase II
results indicating that sunitinib could provide beneﬁt to patients
with pNET [7] were conﬁrmed by a placebo-controlled phase III
trial conducted in 171 patients with well-differentiated, malignant
pNET. This trial was discontinued early after an independent data
review showed greater mortality (21 vs. 9 deaths) and inferior
PFS (median 5.5 months vs. 11.4 months) in the placebo group
[8]. The hazard ratio (HR) for progression or death with sunitinib
was 0.42 (95% conﬁdence interval [CI] 0.26–0.66; p < 0.001); the
HR for death alone was 0.41 (95% CI 0.19–0.89; p = 0.02) in the ﬁrst
reported analysis. Similar results were reported from a retrospec-
tive analysis of patients treated in routine clinical practice [9].
Sunitinib is also approved for the treatment of metastatic renal
cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST)
after imatinib therapy. A difference in sunitinib dosing schedules
for pNET and RCC/GIST (see below), together with the potential
impact of disease-speciﬁc co-morbidities in pNET, provides a
rationale for the development of toxicity management guidelines
speciﬁcally for the various healthcare providers treating patients
with pNET. Furthermore, as a new treatment modality for pNET
directed against a new target, the side-effect proﬁle of sunitinib
differs substantially from established pNET therapies and may be
unfamiliar to healthcare providers who have previously treated
patients with established cytotoxic agents. Speciﬁc guidance on
sunitinib therapy management in pNET will thus be of beneﬁt
and interest to all multidisciplinary team members who partici-
pate in patient care, including medical oncologists, endocrinolo-
gists, gastroenterologists, nurses, dermatologists, podiatrists, and
nutritionists. However, as sunitinib has longer-standing approval
for RCC and GIST, the relative wealth of experience of side-effect
management in these tumor types, from both clinical trials and
clinical practice, will be drawn upon as a rich initial starting point
for the optimization of disease management in patients with pNET.Sunitinib dosing and titration
The recommended dosing regimen for pNET is 37.5 mg taken
orally once daily continuously without a scheduled off-treatment
period (continuous daily dosing [CDD]) [10]; this differs from the
dosing regimen for GIST and advanced RCC, which is one 50 mg
oral dose taken once daily, on a schedule of 4 weeks on treatment
followed by 2 weeks off (Schedule 4/2).
Factors impacting on the development of the CDD dosing
regimen included efﬁcacy, safety, ﬂexibility of dosing, and conve-
nience. Based on similar pharmacokinetic parameters, speciﬁcally
mean dose-corrected trough concentrations, for sunitinib and its
active metabolite SU12662 on a CDD schedule in a phase II study
of patients with GIST [11] and on Schedule 4/2 in a phase III trial
in the same tumor type [12], a CDD of 37.5 mg might reasonably
be expected to deliver the equivalent dose-intensity over a 6-week
period and same overall plasma exposure without intervals off
treatment. Furthermore, data from RCC studies suggested an off-
treatment rebound in putative pharmacodynamic biomarkers
(including plasma VEGF and plasma sVEGFR-2) [13,14]. In contrast,on-treatment changes in levels of these soluble proteins were sus-
tained throughout treatment on a CDD schedule [15]. Thus, there
was a theoretical possibility that a CDD regimen might offer an
efﬁcacy advantage. Recently, Schedule 4/2 and CDD have been
directly compared in the renal EFFECT trial. This trial reported that,
for the treatment of RCC, there was no signiﬁcant difference in the
incidence of commonly reported adverse events (AEs), but there
was a statistically signiﬁcant difference in favor of Schedule 4/2
in ‘time to deterioration’, a composite endpoint of death,
progression, and disease-related symptoms [16]. The investigators
concluded that adherence to the approved 50 mg dose adminis-
tered on Schedule 4/2 remains the treatment goal for patients with
RCC.
The conclusion from the renal EFFECT trial that adherence to
dose and schedule is the key therapy goal is fundamental to main-
taining treatment efﬁcacy with sunitinib. Although the sunitinib
prescribing information recommends dose interruptions and/or
dose adjustments of 12.5 mg increments based on individual safety
and tolerability [10], it is preferable to avoid deviating from the
approved dose and schedule where possible. This approach is
underpinned by results of a meta-analysis of sunitinib trial data,
mainly from patients with RCC or GIST, which showed that higher
exposure to sunitinib was associated with longer time to tumor
progression, longer overall survival (OS), a higher probability of
objective response, and greater tumor shrinkage [17]. In the same
analysis, increased exposure to sunitinib was also associated with
increased incidence of speciﬁc AEs, namely fatigue, neutropenia,
and diastolic hypertension. Moreover, it is becoming apparent that
speciﬁc AEs may actually be biomarkers of treatment effect, as
might be expected for on-target toxicities arising from the mode
of action of sunitinib [18]. Although emerging biomarker data per-
tain to RCC and GIST and require prospective conﬁrmation [19–24],
these data provide a compelling rationale for managing AEs in a
proactive and timely manner in order to maintain dose intensity
and compliance with therapy in the long term, thereby allowing
efﬁcacy to be maintained.
In accordance with prescribing information for sunitinib, a dose
reduction should be considered where sunitinib is co-administered
with strong CYP3A4 inhibitors or grapefruit juice, and a dose
increase may be necessary if patients are receiving CYP3A4
inducers.
Adverse-event proﬁle
In the pNET phase III trial, the most frequently occurring AEs in
patients treated with sunitinib 37.5 mg/day on a CDD schedule
were diarrhea (59% of patients), nausea (45%), asthenia (34%),
vomiting (34%), and fatigue (32%), mainly of grade 1 or 2 severity,
although diarrhea, asthenia, and fatigue were of grade 3 or 4
severity in 5% of patients [8,10,16]. Events occurring at similar fre-
quencies in patients receiving sunitinib and those on placebo were
vomiting (34% vs. 30%), asthenia (34% vs. 27%), and fatigue (32% vs.
27%). In the sunitinib arm, neutropenia was reported as a grade 3/4
AE in 12% of patients and hypertension was the most frequently
reported grade 3/4 non-hematologic AE (10%) [8]. This frequency
pattern of AEs is consistent with that seen in earlier trials of suni-
tinib (CDD) in a variety of tumor types [11,15,25]. It is also similar
to the AE proﬁles reported from a phase II study of carcinoid and
pNETs (Table 1) [7,8] and from the RCC phase III trial [10], both
of which utilized Schedule 4/2 dosing, as well as the randomized
phase II RCC study that directly compared Schedule 4/2 and CDD
[16].
Discontinuation due to AEs occurred in 15% of patients who
received sunitinib in the phase III pNET trial; the AEs most
frequently associated with discontinuation were fatigue (4%),
diarrhea (2%), and cardiac failure (2%) (Table 2) [7,8,11,15,16,25].
Table 1
Adverse events occurring in >15% of patients with pNET receiving sunitinib on a CDD schedule in the phase III trial, and patients with carcinoid or pNET receiving sunitinib
administered according to Schedule 4/2 in the phase II trial.
Event pNET Phase III CDDa sunitinib N = 83 [8] Carcinoid and pNET Phase II Schedule 4/2b sunitinib N = 107 (pNET n = 66) [7]
All grades, n (%) Grade 1 or 2, n (%) Grade 3 or 4, n (%) All grades, n (%) Grade 1 or 2, n (%) Grade 3 or 4, n (%)
Diarrhea 49 (59) 45 (54) 4 (5) 70 (65) 65 (61) 5 (5)
Nausea 37 (45) 36 (43) 1 (1) 57 (53) 51 (48) 6 (6)
Asthenia 28 (34) 24 (29) 4 (5) NR NR NR
Vomiting 28 (34) 28 (34) 0 32 (30) 25 (23) 7 (6)
Fatigue 27 (32) 23 (28) 4 (5) 95 (89) 69 (64) 26 (24)
Hair-color changes 24 (29) 23 (28) 1 (1) 34 (32) 34 (32) 0
Neutropenia 24 (29) 14 (17) 10 (12) 90 (84) 54 (50) 36 (34)
Abdominal pain 23 (28) 19 (23) 4 (5) NR NR NR
Hypertension 22 (26) 14 (17) 8 (10) 17 (16) 6 (6) 11 (10)
HFS 19 (23) 14 (17) 5 (6) 18 (17) 16 (15) 2 (2)
Anorexia 18 (22) 16 (19) 2 (2) 30 (28) 27 (25) 3 (3)
Stomatitis 18 (22) 15 (18) 3 (4) 34 (32) 32 (30) 2 (2)
Dysgeusia 17 (20) 17 (20) 0 52 (49) 52 (49) 0
Epistaxis 17 (20) 16 (19) 1 (1) NR NR NR
Headache 15 (18) 15 (18) 0 25 (23) 24 (22) 1 (1)
Insomnia 15 (18) 15 (18) 0 11 (10) 11 (10) 0
Rash 15 (18) 15 (18) 0 28 (26) 27 (25) 1 (1)
Thrombocytopenia 14 (17) 11 (13) 3 (4) 73 (68) 64 (60) 9 (8)
Mucosal inﬂammation 13 (16) 12 (14) 1 (1) 11 (10) 8 (8) 3 (3)
Weight loss 13 (16) 12 (14) 1 (1) NR NR NR
Constipation 12 (14) 12 (14) 0 NR NR NR
Back pain 10 (12) 10 (12) 0 NR NR NR
CDD, continuous daily dosing; HFS, hand–foot syndrome; NR, not reported; pNET, pancreatic neuroendocrine tumor.
a Raymond et al. [8] adverse events were deﬁned on the basis of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Events listed
are those of any grade that occurred in >15% of patients in either the sunitinib arm (shown above) or the placebo arm (please refer to Raymond et al.) [8].
b Kulke et al. [7] adverse events were deﬁned on the basis of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 2.0. Events listed are
those of any grade that occurred in >10% of patients and also occurred in the phase III study in either the sunitinib or the placebo arm. Adverse events occurring in >15% (all
grades) of the patients in the phase II study, but not reported in the phase III study, were: skin discoloration (36.5%), glossodynia (33.6%), myalgia (32.8%), oral pain (24.3%),
ﬂushing (19.6%), dyspepsia (18.7%), paresthesia (17.8%), and periorbital edema (15.9%).
Table 2
Dose intensity, dose adjustments, and discontinuations related to safety in studies of sunitinib.
Study No. of patients Dose intensity (%) Dose reductions (%) Dose interruptions (%) Discontinuation due to AEs (%)
CDD (37.5 mg daily) in various cancers
George et al. [11] Phase II GIST 60 NR 23 77 7
Escudier et al. [15] Phase II RCC 107 93 43 65 15
Novello et al. [25] Phase II NSCLC 47 NR 29.8 36.2 25.5
Raymond et al. [8] Phase III pNET 86 sunitinib 91.3 31 30 17
85 placebo 100.6 11 12 8
Motzer et al. [16] Phase II RCC 143 78 43 62 17
Schedule 4/2 in various cancers
Motzer et al. [16] Phase II RCC 146 91 36 65 16
Kulke et al. [7] Phase II 107
(41 carcinoid and 66 pNET)
NR 47.7 62.6 10.2
AE, adverse event; GIST, gastrointestinal stromal tumor; NR, not reported; NSCLC, non-small cell lung cancer; pNET, pancreatic neuroendocrine tumor; RCC, renal cell
carcinoma.
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of discontinuations due to AEs ranged from 7% to 25.5% across the
various tumor types in which CDD of sunitinib has been studied
(Table 2) [7,8,11,15,16,25]. For comparison, 10.2% of patients with
carcinoid or pNET receiving sunitinib on Schedule 4/2 discontinued
due to AEs (Table 2) [7] and very similar discontinuation rates were
reported when the two dosing schedules were directly compared
in RCC (Table 2) [16].
Management of toxicities
The welcome advent of more efﬁcacious therapies directed
against new molecular targets in pNET is associated with a unique,
and potentially unfamiliar, range of toxicities. Therapy manage-
ment for targeted agents poses new challenges for healthcare pro-
fessionals and, ultimately, for patients. Successful disease
management requires a multi-stranded approach incorporating
proactive AE prevention, AE management (with vigilant monitoringto allow early intervention and thus the possibility of preventing
deterioration), and patient education [26]. We describe methods
by which these goals may be achieved for speciﬁc toxicities
associated with sunitinib. In addition, as a result of the experience
of the safety proﬁle of sunitinib in clinical trials, the sunitinib
prescribing information recommends that a number of parameters
should be monitored at baseline and during sunitinib treatment
[10]. We intend to provide guidance for physicians and patients
encountering these events in the clinic, outside of the proscriptive
environment of clinical trial protocols. As a practical guide to
AE management, Table 3 provides ‘at a glance’ actions and
considerations to aid healthcare providers who are unfamiliar with
toxicities that may occur during treatment with sunitinib.
Fatigue
Fatigue and asthenia were frequently reported AEs in the pNET
phase III trial, occurring at 32% and 34% overall, respectively; rates
Table 3
Recommended management strategies for key sunitinib-related toxicities by treatment stage and toxicity grade.a
Adverse
event
Baseline assessment During therapy Toxicity grade 1–2b Toxicity grade 3–4b
Hypertension
Action Measure BP Monitor BP (may include
home monitoring)
BP < 160/<100 (but elevated, i.e.P140 /
P90)
Vasodilatory antihypertensive agents
(e.g., ACE inhibitors and angiotensin II
receptor antagonists) are preferred to
calcium channel blockers (see below),
diuretics and b-blockers
BPP 160/P100
Interrupt sunitinib temporarily until
hypertension is under control
Grade 3: withhold dose until toxicity is
grade 61 or BP has returned to baseline,
then resume treatment at the same
dose level. If the toxicity recurs with
grade 3 severity, reduce the dose by 1
level
Grade 4: withhold dose until toxicity is
grade 61 or has returned to baseline,
then reduce the dose by 1 level and
resume treatment, or discontinue at the
discretion of the clinician
Notes Actively screen for hypertension and
treat as appropriate
If sunitinib is interrupted to
enable control of
hypertension, treatment
may be resumed once BP is
appropriately controlled
Avoid CYP4503A4 inhibitors such as
diltiazem and verapamil (calcium
channel blockers); this is not an issue
with the dihydropyridine class of
calcium channel blockers [28]
Use caution with b-blockers and
calcium channel blockers that cause PR
elongation
Uncontrolled hypertension is associated
with onset of cardiotoxicity
Refer to national or institutional
guidelines according to local practice
Fatigue
Action Establish baseline activity levels Monitor and grade fatigue Continue at same dose level Interrupt sunitinib temporarily until
fatigue is grade 61 or has returned to
baseline
Grade 3: then resume treatment at the
same dose level. If the toxicity recurs
with grade 3 severity, reduce the dose
by 1 level
Grade 4: then reduce the dose by 1 level
and resume treatment, or discontinue
at the discretion of the clinician
Notes Institute preventive measures:
adequate nutrition, moderate exercise,
counselling regarding lifestyle
Responds to interruption of
therapy, if necessary
Consider alternative physical cause (e.g., anemia, thyroid dysfunction, insomnia,
dehydration, etc.) or psychological cause (e.g., depression)
Oral mucositis/stomatitis
Action Ensure good oral hygiene Monitor and grade oral
mucositis
Continue at same dose level Interrupt sunitinib temporarily until
mucositis/stomatitis is grade 61 or has
returned to baseline
Grade 3: then resume treatment at the
same dose level. If the toxicity recurs
with grade 3 severity, reduce the dose
by 1 level
Grade 4: then reduce the dose by 1 level
and resume treatment, or discontinue
at the discretion of the clinician
Notes Consider early use of mouthwashes
containing steroids, antibiotics,
antifungals or anaesthetics, as
appropriate
Mouthwashes containing
alcohol should be avoided
Hot, spicy or acidic foods
may exacerbate symptoms
Advise use of soft toothbrushes and sensitive/pediatric toothpaste
Dose reductions are not usually necessary for oral mucositis alone; however,
consider interruption or dose modiﬁcation for multiple toxicities
Skin rash/hand–foot syndrome
Action Skin examination Re-examine and grade skin
toxicity
Continue at same dose level Interrupt sunitinib temporarily until
skin rash/hand–foot syndrome is under
control
Grade 3: withhold dose until toxicity is
grade 61 or has returned to baseline,
then resume treatment at the same
dose level. If the toxicity recurs with
grade 3 severity, reduce the dose by 1
level
Grade 4: withhold dose until toxicity is
grade 61 or has returned to baseline,
then reduce the dose by 1 level and
resume treatment, or discontinue at the
discretion of the clinician
Notes Patient education is essential:
moisturize hands and feet (including
the use of urea-based creams [29]),
avoid rubbing (e.g., ill-ﬁtting shoes),
manicure/pedicure, etc.
Skin toxicity may be reduced
by avoiding hot showers,
reducing sun exposure, and
wearing loose-ﬁtting
clothing
May require removal of blisters or use of hydrocolloidal dressings
May require strong analgesia (topical or systemic)
Monitor for superadded infection which may require antibiotics
May require referral to a dermatologist
(continued on next page)
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Table 3 (continued)
Adverse
event
Baseline assessment During therapy Toxicity grade 1–2b Toxicity grade 3–4b
Diarrhea
Action Establish baseline function Monitor and grade diarrhea Continue at same dose level Interrupt sunitinib temporarily until
diarrhea is under control
Grade 3: withhold dose until toxicity is
grade 61 or has returned to baseline,
then resume treatment at the same
dose level. If the toxicity recurs with
grade 3 severity, reduce the dose by 1
level
Grade 4: withhold dose until toxicity is
grade 61 or has returned to baseline,
then reduce the dose by 1 level and
resume treatment, or discontinue at the
discretion of the clinician
Notes Advice: avoid caffeine, lactose-
containing foods, fatty or high-ﬁber
foods and fruits (except pectin-
containing fruit [e.g., apples and
bananas); keep well hydrated
Consider alternative causes:
pancreatic insufﬁciency
(steatorrhea), infection,
drugs (e.g., laxatives,
antibiotics, etc.)
Oral hydration
Oral anti-diarrheals
As above + supportive measures (e.g.,
intravenous ﬂuids)
Consider infective diarrhea and treat
appropriately
Hematologic toxicity
Action Check baseline blood count Complete blood counts
should be performed at the
beginning of each treatment
cycle
Continue at same dose level Grade 3: withhold dose until toxicity is
grade 62 or has returned to baseline,
then resume treatment at the same
dose level. If the toxicity recurs with
grade 3 severity, at the discretion of the
clinician, reduce the dose by 1 level
Grade 4: withhold dose until toxicity is
grade 62 or has returned to baseline,
then reduce the dose by 1 level and
resume treatment
Notes Additional monitoring if
suspicion of infection (e.g.,
fever, chills, prolonged viral
infection, etc.) or bleeding
Consider prophylactic antibiotic
treatment if prolonged neutropenia
merits
Neutropenia with concomitant
infection may be treated with
granulocyte-colony stimulating factor
(NCCN treatment guidelines for
prevention and treatment of cancer-
related infections) [30]
Thyroid dysfunction
Adverse
event
Baseline assessment During therapy Hypothyroidism Hyperthyroidism
Action TSH at baseline Re-check every 12 weeks or
symptom-directed
Thyroxine replacement therapy (in line
with institutional standard)
Treat hyperthyroidism (in line with
institutional standard)
Notes Additional thyroid tests only as
clinically indicated; follow-up based
on institutional standard (may include
free T4, T3, thyroglobulin)
Aim to keep TSH in normal
range
Dose modiﬁcations of sunitinib usually not required
May require involvement of endocrinologist
ACE, angiotensin-converting enzyme; BP, blood pressure; NCCN, National Comprehensive Cancer Network; TSH, thyroid-stimulating hormone.
a Recommendations are based on information in the study protocol for the placebo-controlled phase III trial of sunitinib in pNET [8], which was based on data from a
phase I study of sunitinib [27], and from studies of sunitinib in renal cell carcinoma (except where speciﬁcally referenced otherwise).
b Toxicity CTCAE v4.0.
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receiving sunitinib discontinued due to fatigue. Recent retrospec-
tive analyses of data from sunitinib trials in RCC and GIST have
linked asthenia and fatigue with improved outcomes, tentatively
identifying these AEs as potential biomarkers of sunitinib efﬁcacy
[22,31]. Fatigue, often the most limiting toxicity associated with
sunitinib treatment, develops during the ﬁrst month of treatment,
with the highest incidence frequently noted after 2–3 months. It
should, however, be remembered that clinical presentation of fati-
gue does not necessarily reﬂect the underlying cause. Fatigue may
be a treatment-induced event per se; however, it may also result
from confounding side effects (such as hypothyroidism or asthe-
nia), or incidental events (for example, occult tumor hemorrhage
and related anemia), underlying disease, or may result from emo-
tional distress or depression, physical distress, or dehydration
[32,33]. Fatigue arising from confounding side effects requiresmanagement speciﬁc to the underlying event; analytical abnor-
malities indicative of, for example, anemia or hypothyroidism
should be corrected, and disease- and treatment-related
co-morbidities such as anorexia and cachexia should be closely
monitored [32,34]. Key preventative and supportive management
approaches are summarized in Table 3. Some patients may
require an initial reduction to a 25 mg dose [4], with a number
subsequently needing an intermittent dosing schedule at this dose
(2 weeks on therapy followed by 1 week off therapy [Schedule
2/1], which has been associated with reduced toxicity in patients
with metastatic RCC [35]).
Oral toxicity, stomatitis, and mucositis
Although an overall stomatitis rate of 22% was reported in the
phase III pNET trial, treatment with sunitinib is associated with a
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tion presents a composite AE ‘stomatitis/oral syndromes’ capturing
a wider range of relevant AE reporting terms, with dysgeusia
reported separately [10]. The rate documented for ‘stomatitis/oral
syndromes’ is 48% with a grade 3/4 rate of 6%, very similar to the
rates reported for stomatitis/mucositis for RCC [10]. In contrast
to the oral toxicities associated with cytotoxic chemotherapy and
arising from local tissue damage and inﬂammation, those seen
with sunitinib appear to stem from functional irritation of the
mucosa and the underlying mechanisms are yet to be elucidated
[32]. Mucositis often occurs during the ﬁrst month of treatment,
but the highest severity is seen during the second and third
months [27]. Symptomatic management of sunitinib oral toxicities
is via dietary modiﬁcation and oral care, with early intervention
achieving better control of mucositis (Table 3). As might be
expected from the preponderance of grade 1/2 events, dose adjust-
ments/interruptions for oral toxicity are seldom necessary. Dose
modiﬁcation should, however, be employed for more severe toxic-
ities and is associated with rapid symptom relief.
Dermatologic AEs: rash and hand–foot syndrome (HFS)
Several dermatologic AEs were among the frequently reported
AEs in the phase III pNET trial. Hair color changes occurred in
29% of patients (1% grade 3/4), palmar–plantar erythrodysesthesia
(hand–foot syndrome; HFS) in 23% (6% grade 3/4), rash in 18% (0%
grade 3/4), and dry skin in 15% of patients (0% grade 3/4). The
dermatologic effects of sunitinib are potentially explained by
deregulation of signaling pathways; a paracrine feedback loop
initiated by VEGF links keratinocytes and endothelial cells, and
stromal secretion of PDGF from matrix ﬁbroblasts may play a role
in the biology of the skin dermis (reviewed by Aparicio-Gallego
et al) [18]. It is also possible that VEGF may be involved in the for-
mation and repair of skin capillaries or that skin toxicity may arise
from the action of sunitinib on the focal adhesion kinase (FAK)
pathway (Aparicio-Gallego et al 2011 and references therein)
[18]. Hair depigmentation (Fig. 1) may result from inhibition of
c-KIT signaling as this pathway is integral to melanocyte prolifera-
tion, differentiation, and pigment production [32,36,37].
As with sunitinib in RCC, in pNET skin rashes rarely require dose
reduction and symptoms tend to decrease over time. Measures to
manage rash are outlined in Table 3.
Hand–foot syndrome, characterized by alterations in the dermal
vasculature and minor endothelial changes at grades 1 and 2, and
more extensive vascular changes combined with layers of keratino-
cyte necrosis and intra-epidermal cleavage at grade 3 and 4, can be a
painful and debilitating condition. A number of possible underlying
mechanisms have been identiﬁed (reviewed by Kollmannsberger9002tcO7002tcO
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Fig. 1. Example of hair and skin depigmentation following chronic treatment with
sunitinib.and colleagues) [32]. However, it seems likely that sunitinib dis-
rupts endothelial cell survival and repair mechanisms and, when
these mechanisms are inhibited in the high-pressure areas of the
hands and feet (which are subject to routine daily trauma through
activities such as walking and hand washing), these areas fail to
repair and develop the characteristics of HFS [32,36].
Patient education regarding HFS is perhaps more important
than for other sunitinib-associated AEs. Ideally, patients should
be encouraged to take care of their hands and feet from the onset
of treatment, including the use of urea-based creams [29] (Table 3).
Gastrointestinal symptoms
Gastrointestinal (GI) toxicities were prominent among patients
treated with sunitinib in the phase III pNET trial; however, little is
known about the causative mechanism [18,32]. Although the
majority of patients treated on this trial experienced diarrhea
(59%), for most patients the severity of diarrhea was mild or mod-
erate; severity increased (grade 3/4) in only 5% of patients [8,10].
Typically, the onset of sunitinib-associated diarrhea occurs after
approximately 3 weeks of therapy and is rarely seen to initiate
beyond 6 months. It is sometimes difﬁcult to distinguish suniti-
nib-associated diarrhea from diarrhea derived from the disease
or from that resulting from the somatostatin analogs that are com-
monly administered to these patients. A number of preventative
and supportive measures have been put forward for controlling
diarrhea (see Table 3). Clinical experience with sunitinib CDD in
pNETs has shown that severe diarrhea rapidly resolves a few days
following treatment discontinuation. However, most cases of diar-
rhea occurring in sunitinib-treated patients with pNET are grade
1–2 and are generally managed successfully by oral hydration
and oral antidiarrheal agents. Dose modiﬁcation is rarely neces-
sary. During the phase III pNET trial, grade 3–4 non-hematologic
toxicities triggered treatment interruption until symptoms
resolved to grade 61, with reintroduction of sunitinib either at
the same dose level (reinforcing patient education for grade 3 tox-
icity) or at the lower dose level of 25 mg.
Nausea and vomiting occurred at frequencies of 45% and 34%,
respectively, in the phase III pNET trial but, as with diarrhea, these
AEs were generally mild or moderate in severity and grade 3/4
events were rare [4,8,10]. As with fatigue, nausea and vomiting
in pNET are not necessarily related to sunitinib treatment. When
treating nausea and vomiting in patients with pNET, co-morbidi-
ties such as altered levels of electrolytes arising from diarrhea
(e.g., hyponatremia, hypokalemia), fatigue, and hyporexia should
be considered and treated as appropriate. Preventative measures
for nausea and vomiting are dietary: a bland diet is recommended,
with small portions taken frequently, and with a higher than cus-
tomary intake of ﬂuids. Spicy, fatty, and salted foods should be
avoided. Early treatment with anti-emetic agents such as metoclo-
pramide or alizapride is desirable, while administration of proton
pump inhibitors will protect the mucosa [33,34,36]. However, as
proton pump inhibitors may interfere with sunitinib absorption
and metabolism, they are not recommended to be administered
within 2 h of sunitinib [34]. Ondansetron and other related drugs
are not routinely recommended for the treatment of vomiting
induced by sunitinib since they may interfere with the metabolism
of sunitinib through the CYP3A4 pathway. Dose adjustments
should seldom be necessary for nausea and vomiting but, as for
diarrhea, severe events should result in dose adjustments as they
did in the phase III trial.
Thyroid dysfunction
Hypothyroidism was reported in 6/83 patients (7%) receiving
sunitinib in the phase III pNET trial; all cases were grade 1/2 in
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lates thyroid function are yet to be deﬁned, candidates include
antiangiogenic effects, inhibition of iodine uptake, destructive thy-
roiditis, thyroid peroxidase inhibition, and reduction of vascularity
by capillary regression and/or constriction [18,36,38]. For sunitinib
in RCC, hypothyroidism was reported as early as 1–2 weeks after
initiation of therapy and the incidence tended to increase over time
[32]. In addition, a recent meta-analysis reported a relationship
between longer duration of sunitinib treatment and increased
incidence of all-grade hypothyroidism [39]. Based on our clinical
experience, we suspect that the onset of hypothyroidism in pNET
treated with sunitinib is later than is seen with the higher dose
used to treat RCC; data are, however, currently lacking.
A number of authors have proposed algorithms for treating
hypothyroidism in patients with RCC [32,38,40], which concur that
regular surveillance of thyroid function is warranted from baseline
onwards. Overt hypothyroidism should be treated with hormone
replacement therapy utilizing typical doses of levothyroxine to
normalize concentrations of thyroid-stimulating hormone (TSH)
and resolve symptoms. Asymptomatic subclinical hypothyroidism
should be monitored and treated if hypothyroidism becomes overt
[32,38]. For patients with pNET, we recommend that thyroid func-
tion tests are checked at least every 12 weeks unless concomitant
symptoms (e.g., fatigue) suggest thyroid dysfunction (Table 3).
Sunitinib dose modiﬁcations for thyroid dysfunction are generally
not required; the condition is usually treated with hormone
replacement therapy and the dose maintained. However, should
dose modiﬁcation be implemented for grade 3 or 4 events, hor-
mone replacement therapy should be closely monitored in order
to avoid hyperthyroidism and possible cardiovascular events.
Neutropenia
As has been noted in patients with RCC [18], most patients with
pNET receiving sunitinib develop hematologic toxicity. Neutrope-
nia is the most commonly observed hematologic toxicity and is
the one associated with the highest incidence of grade 3/4 severity
[10]. The phase III trial in patients with pNET reported neutropenia
as an AE in 29% of patients receiving sunitinib according to the CDD
schedule, with 12% experiencing grade 3/4 severity [8]. Despite
identiﬁcation of this as laboratory ﬁnding, there were no reported
cases of febrile neutropenia [8]. For sunitinib in RCC, neutropenia is
reported as occurring mainly during the ﬁrst treatment cycle, with-
out progression in later cycles, and is usually short-lived [36].
Neutropenia arising from sunitinib treatment of patients with
pNET appears to be linked to neutrophil margination, rather than
true neutropenia. This conclusion is based on observed cases of
neutrophil levels returning to the normal range within 24 h of cor-
ticosteroid administration.
Table 3 outlines preventative measures and treatments for
hematologic toxicity.
Cardiovascular events and hypertension
Hypertension was experienced by 26% of patients with pNET
receiving sunitinib in the phase III trial; 10% of patients had events
of grade 3/4 severity [8,10]. Retrospective analyses of experience
from treatment of RCC and GIST has demonstrated that hyperten-
sion is an on-target effect of sunitinib associated with improved
clinical outcomes. The incidence of hypertension-related AEs is
generally low and manageable [19,20]. Hypertension is a promi-
nent class-effect AE associated with VEGF-1 targeted treatment
(tyrosine kinase inhibitors and bevacizumab) [20,41]. Recent
guidelines for the management of hypertension in patients treated
with anti-angiogenic agents concluded that dose reductions, sche-
dule changes, and treatment discontinuations are rarely necessary,with the majority of patients well controlled with one or two anti-
hypertensive medications [41]. We have also found this to be the
case in patients with pNET treated with sunitinib. In patients with
RCC, Larochelle and co-workers noted that the need for antihyper-
tensive therapy is dictated by the magnitude of the rise in blood
pressure, the underlying cardiovascular status of the patient, and
additional risk factors that may be present [41]. Furthermore,
cardiovascular damage is not usually associated with short-term
increases in blood pressure [41]. All of these key points also pertain
to patients with pNET treated with sunitinib.
Preventive and supportive measures are summarized in Table 3.
Antihypertensive therapy should be closely monitored during sun-
itinib dose adjustment in order to avoid the induction of
hypotension.
QT-prolongation. Sunitinib has been associated with cardiovas-
cular events when used to treat patients with RCC or GIST
[10,42,43]. Only hypertension was reported as frequently occur-
ring in the pNET study [8]. However, the sunitinib prescribing
information states that sunitinib has been shown to prolong the
QT interval in a dose-dependent manner, which may lead to an
increased risk of ventricular arrhythmias including torsade de
pointes (observed in <0.1% of sunitinib-exposed patients) [10].
Sunitinib should therefore be used with caution in patients with
a history of QT interval prolongation, those taking antiarrhythmics,
or those with relevant pre-existing cardiac disease, bradycardia, or
electrolyte disturbances. Periodic monitoring (electrocardiograms
and electrolytes [magnesium, potassium]) should be considered
and additional monitoring for signs and symptoms of congestive
heart failure (CHF) employed. The dose of sunitinib should be
interrupted and/or reduced in patients without clinical evidence
of CHF but with an ejection fraction <50% and >20% below baseline
[10].
Thromboembolic events. These were not reported in patients
treated with sunitinib in the phase III pNET trial. However, should
these events be encountered, they have previously been success-
fully treated with low molecular weight/subcutaneous heparin
for periods of 3–6 months without bleeding complications.
Maintenance or interruption of sunitinib administration during
treatment is at the discretion of the treating physician, but should
be employed for patients in cardiorespiratory compromise with
reintroduction at the same dose level. Sunitinib should, however,
be withdrawn for life-threatening events. Oral anti-vitamin K
should be avoided during heparin treatment as it interacts with
both sunitinib and heparin. Treatment of asymptomatic pulmonary
embolism should be on a patient-by-patient basis, balancing risks
and beneﬁts, and be agreed in consultation with the patient.Discussion
The importance of adhering to therapy, in terms of dose, sche-
dule and duration of treatment, cannot be overstated. Both patient
and physician have key roles to play in achieving this important
goal: physicians in managing side effects to minimize the burden
imposed on patients, and patients in persevering with therapy
and working with physicians on therapy management despite
underlying disease burden. In fact, this is an oversimpliﬁcation as
the treating physician does not, or rather should not, act alone.
Achieving the best supportive care for pNETs requires a multidisci-
plinary team. The multifactorial nature of this disease, with the
possibility of the appearance of carcinoid syndrome, diarrhea,
vomiting, ﬂushing, skin rash, palpitations, and other symptoms
arising from tumor release of various active peptides, makes the
participation of different medical specialties imperative. In
addition, several of the more common side effects of sunitinib
beneﬁt from specialist care. Medical oncologists, oncology nurses,
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gists, nutritionists, and podiatrists are among the specialties that
bring essential expertise to the care of patients with pNET receiv-
ing sunitinib.
Patients must also be fully committed to their treatment goals;
patient education is key to achieving this and also provides some
measure of familiarity in what must be a new and worrying situa-
tion. It is also reasonable to expect that patients who understand
the importance of remaining on therapy at full dose and who are
knowledgeable about the likely side effects and how they can be
treated or avoided will be better placed to work with the medical
team to optimize their duration and experience of therapy.
Furthermore, although data are not currently available in
pNET, preliminary data in RCC and GIST suggest that certain
AEs may function as biomarkers of sunitinib treatment effect
[21–23,31,44,45], and may be viewed by the patient as positive
indicators of treatment beneﬁt. Patients are likely to be encouraged
if they are made aware that, unlike conventional chemotherapy,
AEs with sunitinib tend to improve over time rather than worsen.
From another perspective, patient education regarding the
importance of adhering to dose and schedule is also critical as
sunitinib is a self-administered agent [34].
Another aspect that should be considered in the practical
management of AEs is that sunitinib side effects fall into two
categories:
(1) those that might limit the dose (e.g., asthenia, HFS) vs.
(2) those that are potentially preventable/treatable (diarrhea,
hypertension, hypothyroidism).
Potentially dose-limiting toxicities are difﬁcult to manage pre-
ventatively/treat and, should the toxicity become severe, are thus
more likely to require dose modiﬁcation/interruption. Patients
who require dose reduction often continue to derive beneﬁt from
treatment. If, however, tumor progression occurs during the ﬁrst
3 months of treatment at the reduced dose, dose re-escalation with
the intent to re-control the disease via optimization of drug expo-
sure should be considered. Preventable/treatable toxicities should
be managed with the intention to maintain dose and schedule as
far as possible while also maintaining quality of life. For example,
analysis of patient-reported outcomes data from the phase III pNET
trial showed that throughout the 10-cycle assessment period there
was no difference between the placebo and sunitinib treatment
groups for global health-related quality of life; cognitive,
emotional, physical, role, and social functioning; or in other symp-
toms and scales with the single clinically signiﬁcant exception of
diarrhea [8], a toxicity that is both preventable and manageable
without dose adjustment. To our knowledge, this type of analysis
has not been conducted for any other targeted agent evaluated
for the treatment of pNET.
In addition to optimizing sunitinib therapy with respect to tox-
icity management (the scope of this review), future studies may
identify other ways to optimize therapy, for example, by further
monitoring pharmacokinetics or evaluating pharmacodynamic
endpoints (e.g. on-target adverse events or biochemical markers).
One such study, an international open-label trial of the efﬁcacy
and safety of sunitinib in patients with progressive, well-differen-
tiated pNET (EudraCT, 2011-004363-74) is recruiting patients
(planned enrollment, n = 80), and, as part of its secondary
outcomes (primary endpoint, PFS), will assess potential relation-
ships between plasma drug concentrations and selected safety,
biomarker, and efﬁcacy endpoints. The insights gained from the
approaches to AE management established in the treatment of
RCC and GIST are a valuable resource and should be used to inform
management strategies in pNET. However, in administering a con-
tinuous daily dose of sunitinib to patients with pNET, physiciansmust be vigilant and continue to optimize care of these patients
as we gain greater experience with this dosing regimen. Ideally,
we should aspire to personalizing therapy and therapy manage-
ment, not only for sunitinib but other targeted therapies, such as
everolimus and, indeed, chemotherapy and radionuclide therapy.
This could be achieved by identifying biomarkers not only for a
better clinical outcome, but also for predicting toxicity. This is
not an unrealistic goal; there are already indications that germ-line
polymorphic variants have the potential to predict both lack of
response and toxic effects in patients with RCC treated with suni-
tinib [46]. In the fullness of time, it is to be hoped that advances of
this type will allow us to select the best treatment options for both
efﬁcacy and experience of therapy for our patients.Conﬂict of interest statement
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